
Heidelberg Pharma AG
XETRA:HPHA

Intrinsic Value
The intrinsic value of one
HPHA
stock under the Base Case scenario is
2.84
EUR.
Compared to the current market price of 2.64 EUR,
Heidelberg Pharma AG
is
Undervalued by 7%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Heidelberg Pharma AG
Fundamental Analysis


Revenue & Expenses Breakdown
Heidelberg Pharma AG
Balance Sheet Decomposition
Heidelberg Pharma AG
Current Assets | 52.4m |
Cash & Short-Term Investments | 36.6m |
Receivables | 3.2m |
Other Current Assets | 12.7m |
Non-Current Assets | 13.4m |
PP&E | 3.5m |
Intangibles | 8.9m |
Other Non-Current Assets | 975.2k |
Free Cash Flow Analysis
Heidelberg Pharma AG
EUR | |
Free Cash Flow | EUR |
Earnings Waterfall
Heidelberg Pharma AG
Revenue
|
8.5m
EUR
|
Cost of Revenue
|
-1.7m
EUR
|
Gross Profit
|
6.8m
EUR
|
Operating Expenses
|
-27.2m
EUR
|
Operating Income
|
-20.4m
EUR
|
Other Expenses
|
1.6m
EUR
|
Net Income
|
-18.8m
EUR
|
HPHA Profitability Score
Profitability Due Diligence
Heidelberg Pharma AG's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

Score
Heidelberg Pharma AG's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
HPHA Solvency Score
Solvency Due Diligence
Heidelberg Pharma AG's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Score
Heidelberg Pharma AG's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HPHA Price Targets Summary
Heidelberg Pharma AG
According to Wall Street analysts, the average 1-year price target for
HPHA
is 12.14 EUR
with a low forecast of 12.02 EUR and a high forecast of 12.5 EUR.
Dividends
Current shareholder yield for HPHA is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
HPHA
stock under the Base Case scenario is
2.84
EUR.
Compared to the current market price of 2.64 EUR,
Heidelberg Pharma AG
is
Undervalued by 7%.